SK286565B6 - Spôsob prípravy (3-kyano-1H-indol-7-yl)[(4-(4-fluórfenetyl)- piperazin-1-yl)]metanónu a jeho solí - Google Patents

Spôsob prípravy (3-kyano-1H-indol-7-yl)[(4-(4-fluórfenetyl)- piperazin-1-yl)]metanónu a jeho solí Download PDF

Info

Publication number: SK286565B6
Authority: SK; Slovakia
Prior art keywords: formula; indole; cyano; salts; ethyl
Prior art date: 2001-01-23

Application number

SK1046-2003A

Other languages

English (en)

Slovak (sk)

Other versions

SK10462003A3 (sk

Inventor

Hel�Ne Crassier

Uwe Eckert

Henning B�Ttcher

Andreas Bathe

Steffen Emmert

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-23

Filing date

2001-12-21

Publication date

2009-01-07

2001-12-21 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2003-12-02 Publication of SK10462003A3 publication Critical patent/SK10462003A3/sk

2009-01-07 Publication of SK286565B6 publication Critical patent/SK286565B6/sk

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
- C07D201/02—Preparation of lactams
- C07D201/04—Preparation of lactams from or via oximes by Beckmann rearrangement
- C07D201/06—Preparation of lactams from or via oximes by Beckmann rearrangement from ketones by simultaneous oxime formation and rearrangement
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Hematology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Addiction (AREA)
Nutrition Science (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1046-2003A 2001-01-23 2001-12-21 Spôsob prípravy (3-kyano-1H-indol-7-yl)[(4-(4-fluórfenetyl)- piperazin-1-yl)]metanónu a jeho solí SK286565B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10102944A DE10102944A1 (de)	2001-01-23	2001-01-23	Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen
PCT/EP2001/015240 WO2002059092A1 (en)	2001-01-23	2001-12-21	Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof

Publications (2)

Publication Number	Publication Date
SK10462003A3 SK10462003A3 (sk)	2003-12-02
SK286565B6 true SK286565B6 (sk)	2009-01-07

Family

ID=7671481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1046-2003A SK286565B6 (sk)	2001-01-23	2001-12-21	Spôsob prípravy (3-kyano-1H-indol-7-yl)[(4-(4-fluórfenetyl)- piperazin-1-yl)]metanónu a jeho solí

Country Status (29)

Country	Link
US (1)	US7312342B2 (de)
EP (1)	EP1353906B1 (de)
JP (1)	JP4215195B2 (de)
KR (1)	KR100820763B1 (de)
CN (1)	CN1213029C (de)
AR (1)	AR032261A1 (de)
AT (1)	ATE269849T1 (de)
AU (1)	AU2002219220B2 (de)
BR (1)	BR0116816A (de)
CA (1)	CA2435426C (de)
CZ (1)	CZ20032202A3 (de)
DE (2)	DE10102944A1 (de)
DK (1)	DK1353906T3 (de)
EC (1)	ECSP034737A (de)
ES (1)	ES2223738T3 (de)
HU (1)	HUP0401039A3 (de)
IL (2)	IL157061A0 (de)
MX (1)	MXPA03006534A (de)
MY (1)	MY126252A (de)
NZ (1)	NZ527779A (de)
PL (1)	PL209416B1 (de)
PT (1)	PT1353906E (de)
RU (1)	RU2295519C2 (de)
SK (1)	SK286565B6 (de)
TR (1)	TR200402142T4 (de)
TW (1)	TW588044B (de)
UA (1)	UA74039C2 (de)
WO (1)	WO2002059092A1 (de)
ZA (1)	ZA200306540B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10246357A1 (de) *	2002-10-04	2004-04-15	Merck Patent Gmbh	Verwendung von 5-HT2Rezeptorantagonisten
DE102004047517A1 (de) *	2004-09-28	2006-03-30	Merck Patent Gmbh	Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
EP2016052B1 (de) *	2006-05-05	2012-06-06	Merck Patent GmbH	Kristalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanon-phosphat
CN101437793B (zh) *	2006-05-05	2012-08-22	默克专利股份有限公司	结晶的（3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）哌嗪-1-基]甲酮磷酸盐
CN102816104B (zh) *	2012-08-30	2014-05-21	浙江大学	一种3-氰基吲哚类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH421107A (de) *	1963-06-04	1966-09-30	Sandoz Ag	Verfahren zur Herstellung neuer heterocyclischer Verbindungen
CA2084531A1 (en) *	1991-12-19	1993-06-20	David W. Smith	Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines

2001
- 2001-01-23 DE DE10102944A patent/DE10102944A1/de not_active Withdrawn
- 2001-12-21 DE DE60104024T patent/DE60104024T2/de not_active Expired - Lifetime
- 2001-12-21 MX MXPA03006534A patent/MXPA03006534A/es active IP Right Grant
- 2001-12-21 CZ CZ20032202A patent/CZ20032202A3/cs unknown
- 2001-12-21 DK DK01273449T patent/DK1353906T3/da active
- 2001-12-21 BR BR0116816-9A patent/BR0116816A/pt not_active Application Discontinuation
- 2001-12-21 ES ES01273449T patent/ES2223738T3/es not_active Expired - Lifetime
- 2001-12-21 RU RU2003124068/04A patent/RU2295519C2/ru not_active IP Right Cessation
- 2001-12-21 PL PL364392A patent/PL209416B1/pl not_active IP Right Cessation
- 2001-12-21 HU HU0401039A patent/HUP0401039A3/hu unknown
- 2001-12-21 SK SK1046-2003A patent/SK286565B6/sk not_active IP Right Cessation
- 2001-12-21 CN CNB018221882A patent/CN1213029C/zh not_active Expired - Fee Related
- 2001-12-21 EP EP01273449A patent/EP1353906B1/de not_active Expired - Lifetime
- 2001-12-21 WO PCT/EP2001/015240 patent/WO2002059092A1/en not_active Ceased
- 2001-12-21 CA CA002435426A patent/CA2435426C/en not_active Expired - Fee Related
- 2001-12-21 KR KR1020037009645A patent/KR100820763B1/ko not_active Expired - Fee Related
- 2001-12-21 IL IL15706101A patent/IL157061A0/xx unknown
- 2001-12-21 JP JP2002559394A patent/JP4215195B2/ja not_active Expired - Fee Related
- 2001-12-21 AU AU2002219220A patent/AU2002219220B2/en not_active Ceased
- 2001-12-21 PT PT01273449T patent/PT1353906E/pt unknown
- 2001-12-21 US US10/466,991 patent/US7312342B2/en not_active Expired - Fee Related
- 2001-12-21 TR TR2004/02142T patent/TR200402142T4/xx unknown
- 2001-12-21 UA UA2003076931A patent/UA74039C2/uk unknown
- 2001-12-21 NZ NZ527779A patent/NZ527779A/xx unknown
- 2001-12-21 AT AT01273449T patent/ATE269849T1/de active
2002
- 2002-01-17 TW TW091100688A patent/TW588044B/zh not_active IP Right Cessation
- 2002-01-18 MY MYPI20020201A patent/MY126252A/en unknown
- 2002-01-23 AR ARP020100222A patent/AR032261A1/es unknown
2003
- 2003-07-22 IL IL157061A patent/IL157061A/en not_active IP Right Cessation
- 2003-08-19 EC EC2003004737A patent/ECSP034737A/es unknown
- 2003-08-21 ZA ZA200306540A patent/ZA200306540B/en unknown

Also Published As

Publication number	Publication date
BR0116816A (pt)	2004-01-27
PL364392A1 (en)	2004-12-13
KR100820763B1 (ko)	2008-04-10
CA2435426A1 (en)	2002-08-01
DK1353906T3 (da)	2004-10-11
RU2003124068A (ru)	2005-01-10
CN1213029C (zh)	2005-08-03
PT1353906E (pt)	2004-11-30
ES2223738T3 (es)	2005-03-01
PL209416B1 (pl)	2011-08-31
DE60104024D1 (de)	2004-07-29
JP2004519466A (ja)	2004-07-02
TW588044B (en)	2004-05-21
ZA200306540B (en)	2004-09-02
CN1487923A (zh)	2004-04-07
TR200402142T4 (tr)	2004-10-21
DE10102944A1 (de)	2002-07-25
NZ527779A (en)	2004-12-24
AR032261A1 (es)	2003-10-29
ECSP034737A (es)	2003-09-24
EP1353906B1 (de)	2004-06-23
SK10462003A3 (sk)	2003-12-02
RU2295519C2 (ru)	2007-03-20
HUP0401039A3 (en)	2008-05-28
HUP0401039A2 (hu)	2004-08-30
UA74039C2 (en)	2005-10-17
WO2002059092A1 (en)	2002-08-01
CA2435426C (en)	2009-10-27
CZ20032202A3 (cs)	2004-01-14
HK1063182A1 (en)	2004-12-17
AU2002219220B2 (en)	2007-01-11
ATE269849T1 (de)	2004-07-15
DE60104024T2 (de)	2005-07-07
MXPA03006534A (es)	2003-09-22
US20040063723A1 (en)	2004-04-01
KR20030068590A (ko)	2003-08-21
EP1353906A1 (de)	2003-10-22
JP4215195B2 (ja)	2009-01-28
IL157061A (en)	2009-09-01
MY126252A (en)	2006-09-29
US7312342B2 (en)	2007-12-25
IL157061A0 (en)	2004-02-08

Publication	Publication Date	Title
WO2000059912A1 (en)	2000-10-12	Thienopyrimidine compounds and salts thereof and process for the preparation of the same
JPH02142791A (ja)	1990-05-31	ピロロカルバゾール誘導体、それらの調製方法およびそれらの医薬として使用
SK287018B6 (sk)	2009-09-07	Deriváty fenylpiperazínov, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie
NZ586775A (en)	2012-07-27	6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
US5436264A (en)	1995-07-25	N-aryloxyalkyl tryptamine α1 -adrenergic receptor antagonists
FI85478B (fi)	1992-01-15	Foerfarande foer framstaellning av terapeutiskt anvaendbara -karbolinderivat.
IL179371A (en)	2012-07-31	3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors
SK286565B6 (sk)	2009-01-07	Spôsob prípravy (3-kyano-1H-indol-7-yl)[(4-(4-fluórfenetyl)- piperazin-1-yl)]metanónu a jeho solí
JPH07242666A (ja)	1995-09-19	複素環化合物
AU2002219220A1 (en)	2003-02-06	Process for the preparation of (3-cyano-1H-indol-7-YL)(4-(4-fluorophenethyl)piperazin-1-YL)-methanone and salts thereof
CN101010296B (zh)	2011-08-17	烷基羟吲哚的哌嗪衍生物
HK1063182B (en)	2006-03-10	A process for the preparation of 5-ht2a receptor antagonists and salts thereof
MXPA06013064A (es)	2007-04-27	Derivados de piperazina de alquil-oxindoles.
CN1993324B (zh)	2010-12-15	治疗中枢神经系统障碍的3-(((4-苯基)-哌嗪-1-基)-烷基)-3-烷基-1,3-二氢-2h-吲哚-2-酮衍生物和相关化合物
JPH07252255A (ja)	1995-10-03	５，６，７，８−テトラヒドロ−２（１ｈ）−オキソ−１，６−ナフチリジン−３−カルボン酸誘導体およびその塩
JPH03223265A (ja)	1991-10-02	環状ジアミン誘導体
JP2010531887A (ja)	2010-09-30	ベンズイミダゾールチオフェンの調製方法
JPS5823693A (ja)	1983-02-12	イミダゾキノキザリン化合物類
Maruoka et al.	2010	Synthesis of dihydroindoles and tetrahydroquinolines by the intramolecular diels-alder reaction of N-alkenylated 2-acylamino-3-furancarbonitriles
JPH07215968A (ja)	1995-08-15	アゼラスチンの製造方法
JPH07126253A (ja)	1995-05-16	３−クロロピラゾール誘導体およびその製造法
TW200829592A (en)	2008-07-16	Fluoro derivative of quinolin-2(1H)-one, process for the preparation thereof and use thereof as synthesis intermediate

Legal Events

Date	Code	Title	Description
2012-09-03	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20111221